What Click Therapeutics does

Click Therapeutics, Inc. is a New York City-based, venture-backed private digital therapeutics company founded in 2012 by David Benshoof Klein. The company develops, validates, and commercializes software as prescription medical treatments (Prescription Digital Therapeutics, or PDTs) for serious psychiatric, neurological, and cardiometabolic conditions. Its proprietary AI-enabled platform combines the Click Neurobehavioral Intervention (CNI) Platform with the Digital Neuroactivation and Modulation (DiNaMo) paradigm to deliver clinically-validated, smartphone-based cognitive and behavioral interventions that modulate neural circuits involved in depression, migraine, schizophrenia, diabetes, and other conditions. The platform supports both standalone PDTs and Click SE™ Software-Enhanced Drug™ combinations with pharmacotherapy under FDA's PDURS framework.

The company has secured three FDA-authorized products: Rejoyn (CT-152) for adjunctive MDD treatment (FDA-cleared April 2024), CT-132 for episodic migraine prevention (FDA De Novo authorization April 2025), and AspyreRx for type 2 diabetes (acquired via Better Therapeutics in May 2024). Its investigational pipeline spans schizophrenia (CT-155 in Phase III with positive CONVOKE results; CT-156 in Phase 2), opioid use disorder (CT-102 with Indivior), multiple sclerosis (CT-133), atopic dermatitis (CT-171), obesity optimized for GLP-1 combination (CT-181), oncology (CT-191), insomnia (CT-141/Clickadian), and acute coronary syndrome (CT-111/Clickheart). The FDA has granted Breakthrough Device Designations for CT-132, CT-155, and BT-004.

Click generates revenue through three primary streams: (1) licensing royalties and milestone payments from pharmaceutical co-development partners, with disclosed deal values exceeding $500M (Boehringer Ingelheim for CT-155/CT-156) and up to $302M (Otsuka for Rejoyn), plus tiered double-digit royalties on net sales; (2) direct prescription digital therapeutic sales via iOS/Android app stores reimbursed by Medicare and select commercial payers; and (3) B2B Click SE™ enterprise partnerships with pharma companies for software-enhanced drug development. Distribution is multi-channel, including prescription downloads, healthcare provider channels, pharma partner commercialization (Otsuka for Rejoyn globally; Click now leads CT-155 commercialization post-April 2026 restructuring), and OEM/embedded distribution via Ultrahuman's Ring Air smart ring (Migraine PowerPlug, launching early 2026 across the US, Canada, EU, India, and Australia). The company employs ~68 staff post-April 2026 layoffs and is led by founder/CEO David Benshoof Klein alongside a multidisciplinary executive team.

Name

Click Therapeutics

Legal name

Click Therapeutics, Inc.

Website

https://clicktherapeutics.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Click Therapeutics is a New York-based private digital therapeutics company developing FDA-authorized prescription software treatments for psychiatric, neurological, and cardiometabolic conditions, partnering with major pharmaceutical companies (Otsuka, Boehringer Ingelheim) and serving patients via healthcare provider prescriptions and reimbursed app downloads.

Ownership category

akta.pro rank

Product category

Prescription Digital Therapeutics

NAICS

Offices of Physicians (6211), Outpatient Mental Health and Substance Abuse Centers (621420), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)

SIC

Services-Prepackaged Software (7372), Services-Health Services (8000)

akta.pro primary industry

Prescription Digital Therapeutics (PDT) (HLACANAB)

akta.pro secondary industries

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH), Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

Keywords

• Prescription digital therapeutics
• Software-enhanced drugs
• Digital therapeutics platform
• AI-enabled therapeutics
• Neuromodulatory treatments

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Licensing royalties & milestone payments from pharma partners: Click receives upfront payments, R&D funding, regulatory and commercial milestone payments, and tiered (often double-digit) royalties on net sales from pharma co-development partners. From Otsuka: up to $10M upfront/regulatory + ~$20M development funding + $272M in commercial milestones + tiered double-digit royalties on global Rejoyn sales. From Boehringer: original deal value over $500M (CT-155) plus $460M for CT-156 expansion + tiered royalties.
2. Prescription digital therapeutic sales (Rejoyn, CT-132, AspyreRx): Revenue from commercialization of FDA-authorized prescription digital therapeutics via app store downloads and payer (Medicare/private insurance) reimbursement; now extending to in-house commercialization of CT-155 after April 2026 Boehringer restructuring.
3. Click SE™ Software-Enhanced Drug™ B2B platform deals: B2B platform revenue from pharma collaborators developing "SE" (software-enhanced) versions of pipeline or marketed drugs, combining Click's software with their pharmacotherapy to support added clinical benefit claims under PDURS guidance.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Core offering

Click Therapeutics develops, validates, and commercializes software as prescription medical treatments, delivered to patients via smartphone and prescribed by physicians. Its portfolio includes FDA-cleared prescription digital therapeutics (Rejoyn for MDD, CT-132 for episodic migraine, AspyreRx for type 2 diabetes) and the Click SE Software-Enhanced Drug platform that combines the company's digital therapeutics with partner pharmacotherapies to deliver added clinical benefit.

Product overview

Click Therapeutics operates a platform-plus-modules architecture, anchored by its proprietary AI-enabled digital therapeutics platform that combines neuroscience with software to develop, validate, and commercialize software as prescription medical treatments. The mature commercial portfolio includes the FDA-cleared Rejoyn (CT-152) for Major Depressive Disorder, the FDA-authorized CT-132 for episodic migraine prevention, and the FDA-authorized AspyreRx for type 2 diabetes (acquired from Better Therapeutics). The investigational pipeline spans psychiatry, neurology, oncology, immunology, and cardiometabolic diseases, including CT-155 (schizophrenia, Phase III positive), CT-156 (schizophrenia), CT-102 (opioid use disorder), CT-133 (multiple sclerosis), CT-171 (atopic dermatitis), CT-181 (obesity, leveraging AspyreRx), CT-191 (oncology), CT-141/Clickadian (insomnia), and CT-111/Clickheart (acute coronary syndrome). Building on this foundation, Click launched Click SE™ in October 2024 to combine its digital therapeutic technology with pharmacotherapy, creating Software-Enhanced Drug™ therapies under the FDA's PDURS framework. Cross-platform integrations include the Migraine PowerPlug with Ultrahuman's Ring Air smart ring for biomarker-driven migraine management.

Differentiator

Problem solved

Functional benefit

Brands

• Click SE: Click Therapeutics' product offering for Software-Enhanced Drug™ therapies, launched in October 2024 in response to FDA draft guidance on Prescription Drug Use-Related Software (PDURS); combines Click's digital therapeutic technology with pharmacotherapy to create software-enhanced drug treatments with added clinical benefit.
• Rejoyn
• AspyreRx

Products and services

• Click Therapeutics AI-Enabled Digital Therapeutics Platform Proprietary, multimodal, platform-based foundation that combines scientifically proven therapies with proprietary Digital Neuroactivation and Modulation (DiNaMo) mechanisms and AI-based technologies to develop, validate, and commercialize software as prescription medical treatments for patients with unmet medical needs.
• Rejoyn (CT-152) First FDA-cleared prescription digital therapeutic for the adjunctive treatment of Major Depressive Disorder (MDD) symptoms in adults age 22+ on antidepressant medication. Six-week smartphone-delivered treatment combining clinically-validated Emotional Faces Memory Task (EFMT) cognitive emotional training with brief therapeutic lessons; co-developed with Otsuka Pharmaceutical.
• CT-132 First FDA-authorized (De Novo, April 2025) prescription digital therapeutic for the preventive treatment of episodic migraine in adults 18+, for adjunctive use alongside acute and/or other preventive treatments. 12-week clinical intervention modulating sensory, autonomic, and affective neurocircuitry through CBT and evidence-based practices; -3.04 MMD absolute reduction in pivotal ReMMi-D trial.
• AspyreRx FDA-authorized prescription digital therapeutic providing cognitive behavioral therapy to adults 18+ with type 2 diabetes as adjunctive therapy to standard of care. Acquired from Better Therapeutics in May 2024; also received FDA Breakthrough Device Designation for metabolic dysfunction-associated steatohepatitis (MASH). Click is integrating AspyreRx with its AI-enabled platform to optimize CT-181 for combination use with GLP-1s.
• CT-155 Investigational prescription digital therapeutic designed to treat the negative symptoms of schizophrenia as adjunctive therapy to standard of care antipsychotic therapy. FDA Breakthrough Device Designation granted January 2024; co-developed with Boehringer Ingelheim since September 2020. Phase III CONVOKE trial met primary endpoint in August 2025, showing 62% relative improvement in CAINS-MAP.
• CT-156 Investigational prescription digital therapeutic for schizophrenia, added under the expanded Click-Boehringer Ingelheim collaboration (announced December 2022) to address additional unmet needs in schizophrenia. Currently in Phase 2 development/pilot stage, complementing the CT-155 program.
• CT-102 Prescription digital therapeutic candidate for Opioid Use Disorder (OUD), developed in collaboration with Indivior as part of Click's psychiatry, CNS, and pain disorders portfolio. Currently in Phase 2 development/pilot stage.
• CT-133 Prescription digital therapeutic candidate for Multiple Sclerosis (MS) in Click's neurology pipeline. Currently in Phase 1 (Discovery) stage of development.
• CT-171 Prescription digital therapeutic candidate for Atopic Dermatitis in Click's immunology pipeline. Currently in Phase 1 (Discovery) stage of development.
• CT-181 Prescription digital therapeutic candidate for Obesity optimized for combination use with anti-obesity and diabetes medications such as GLP-1s (including current injectables and future oral formulations) to improve treatment persistence, outcomes, and value. Currently in Phase 1 (Discovery) stage, leveraging AspyreRx's clinically validated digital behavioral therapy and Click's AI-enabled platform.
• CT-191 Prescription digital therapeutic candidate for Oncology in Click's oncology pipeline. Currently in Phase 1 (Discovery) stage, including a randomized controlled pilot trial of a neuromodulatory digital therapeutic for individuals with breast cancer (Adler et al., 2025).
• CT-141 (Clickadian) Prescription digital therapeutic candidate branded as Clickadian for Insomnia. Currently in Phase 1 (Discovery) stage of development.
• CT-111 (Clickheart) Prescription digital therapeutic candidate branded as Clickheart for Acute Coronary Syndrome. Currently in Phase 1 (Discovery) stage of development as part of Click's cardiology pipeline.
• Click SE (Software-Enhanced Drug Therapies) B2B product offering that combines Click's patent-protected and clinically validated digital therapeutic technology with pharmacotherapy to create Software-Enhanced Drug treatments, designed to deliver added clinical benefit to patients compared to drug alone and to support label enhancement claims under FDA PDURS guidance for pharmaceutical partners.
• Ultrahuman Migraine PowerPlug Software-based feature integrated into Ultrahuman's Ring Air smart ring platform that combines Ultrahuman's biometric tracking (sleep, HRV, stress, activity) with Click's FDA-authorized CT-132 digital therapeutic technology to deliver biomarker-driven personalized migraine insights and guided behavioral interventions.

Quantifiable outcome

• CT-132 reduced monthly migraine days by -3.04 MMDs vs sham (treatment difference -0.9 MMDs; p=0.005) in 568 ITT participants over 12 weeks
• +4 more outcomes

Named customers1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered major, supporting and flagship.

• UltrahumanmajorTechnology or Integration · 14 January 2026Partnership to develop the Migraine PowerPlug, a biomarker-driven migraine management tool that integrates Click's FDA-authorized prescription digital therapeutic CT-132 with Ultrahuman's smart ring platform. Uses sleep, HRV, stress and activity data to deliver personalized migraine insights and guided behavioral interventions. Scheduled for early 2026 launch in US, Canada, EU, India and Australia.
• Better TherapeuticsmajorStrategic or Co-development Partner · 22 May 2024Click acquired the assets of Better Therapeutics, Inc. in May 2024 to accelerate development in obesity and cardiometabolic disease. Assets included AspyreRx (BT-001, first FDA-authorized PDT for type 2 diabetes), BT-002 (hypertension), BT-003 (hyperlipidemia), and BT-004 (Breakthrough Designation for MASH). Click integrates AspyreRx's clinically validated CBT with its AI-enabled platform to develop CT-181 (obesity) optimized for combination with GLP-1s.
• IndiviorsupportingStrategic or Co-development Partner · 22 May 2024Multi-year collaborative development partnership with Click Therapeutics on CT-102, a prescription digital therapeutic candidate for opioid use disorder (OUD), currently in Phase 2: Dev/Pilot stage.
• Syneos HealthsupportingImplementation/ SI/ Consulting Partner · 2 August 2023Selected by Click Therapeutics as the contract research organization for the ReMMiD-C fully remote decentralized clinical trial in migraine patients on CGRP inhibitor therapy. Syneos Health provides decentralized clinical trial solutions, design expertise and operational execution alongside Click's digital therapeutic delivery via mobile app.
• Verily (Alphabet)supportingTechnology or Integration · 24 February 2021Verily's Project Baseline platform used to execute the fully remote Mirai clinical trial evaluating CT-152 in adults with MDD on antidepressant monotherapy; first-of-its-kind fully remote trial design for MDD leveraging Verily's tools and technology to engage patients and clinicians.
• Boehringer IngelheimflagshipStrategic or Co-development Partner · 11 September 2020Worldwide collaboration to develop and commercialize CT-155, a prescription digital therapeutic for experiential negative symptoms of schizophrenia. Initial deal value over $500M (upfront, R&D funding, milestones, tiered royalties). Expanded December 2022 to add CT-156 (up to $460M additional milestones). CT-155 received FDA Breakthrough Designation January 2024, met primary endpoint in CONVOKE Phase III trial August 2025, and was presented at ECNP October 2025.
• Otsuka PharmaceuticalflagshipStrategic or Co-development Partner · 3 January 2019Co-development and commercialization partnership for CT-152 (Rejoyn), the first FDA-cleared prescription digital therapeutic for adjunctive treatment of MDD symptoms. Signed January 2019; Otsuka committed full development funding, pays Click up to $10M upfront/regulatory + ~$20M development funding + $272M in commercial milestones + tiered double-digit royalties on global sales. Mirai fully-remote pivotal trial launched February 2021 with Verily. FDA cleared Rejoyn in April 2024.

Scale indicators12 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Akili Interactive: Akili Interactive is a leading prescription digital therapeutics company that developed EndeavorRx (FDA-authorized for ADHD in children) and other cognitive digital therapeutics. Akili is the closest direct peer to Click in the prescription digital therapeutics space, competing for the same payer and prescriber mindshare, though Akili has since pivoted toward broader consumer cognitive health offerings.
• Big Health: Big Health developed Sleepio, a prescription digital therapeutic for insomnia, and is expanding into anxiety and depression. Big Health competes directly with Click in CNS-focused PDTs and shares the same regulatory pathway, payer coverage challenges, and pharma partnership opportunities.
• Mahana Therapeutics: Mahana Therapeutics is a digital therapeutics company focused on gastrointestinal conditions (e.g., irritable bowel syndrome) that has secured FDA authorizations and pursues prescription reimbursement. Mahana competes with Click in the prescription digital therapeutics business model and is at a similar pre-commercial or early-commercial stage.
• Welldoc: Welldoc develops prescription digital health solutions for chronic disease management including diabetes (BlueStar, the first FDA-cleared digital therapeutic for type 2 diabetes), cardiovascular, and mental health. Welldoc competes directly with Click in the cardiometabolic PDT space and pursues similar payer and pharma partnership channels.

Broad incumbents

• Omada Health: Omada Health is a leading virtual chronic care company offering digital programs for diabetes prevention, diabetes management, hypertension, and behavioral health. While broader than Click's prescription model, Omada overlaps in cardiometabolic digital therapeutics and competes for similar payer contracts and employer customers.
• Headspace Health: Headspace Health (post-Ginger merger) provides mental health digital therapeutics and telebehavioral health services, including prescription digital mental health offerings. Headspace is a broader incumbent that overlaps with Click's Rejoyn (MDD) target market, though it primarily pursues consumer and employer channels rather than prescription reimbursement.
• Virta Health: Virta Health provides a digitally delivered, clinician-led program to reverse type 2 diabetes and other metabolic conditions. Virta overlaps with Click's AspyreRx and CT-181 (obesity) pipeline in the cardiometabolic digital therapeutics space and pursues similar payer and employer channels.

Emerging players

• Pear Therapeutics (historical): Pear Therapeutics was the prior category leader in prescription digital therapeutics, with FDA authorizations for reSET (substance use disorder), reSET-O (opioid use disorder), and Somryst (insomnia). Pear filed for bankruptcy in April 2023 due to insufficient payer adoption and was acquired by assets purchasers. Pear is the most cautionary historical peer for Click, illustrating both the opportunity and the execution risks in commercializing PDTs.
• Limbic: Limbic is a UK-based digital therapeutics company developing AI-powered cognitive behavioral therapy tools, including a CE-marked digital therapeutic for depression and anxiety, with plans to seek FDA pathway. Limbic overlaps with Click's Rejoyn (MDD) and represents an emerging European competitor in prescription-grade digital mental health.

Others

• Better Therapeutics: Better Therapeutics was a digital therapeutics company that developed AspyreRx (FDA-authorized PDT for type 2 diabetes) and was acquired by Click Therapeutics in May 2024. As the direct acquirer of Better's assets, Click has effectively internalized this peer and inherited its cardiometabolic pipeline (BT-002 hypertension, BT-003 hyperlipidemia, BT-004 MASH).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/click-therapeutics-inc-
• Xx.com/Click_Tx
• Facebookfacebook.com/ClickTherapeutics

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds16 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Click Therapeutics